Deep learning algorithms developed at the Memorial Sloan Kettering Cancer Center (MSK) were able to distinguish prostate, skin and breast cancer with nearly perfect accuracy in a recent clinical trial. The technology has already been licensed exclusively by New York-based startup Paige.AI, which snapped up a $25 million series A early last year to continue to advance it.
Wall Street further embraced Abbott Laboratories as it beat expectations and raised its 2019 guidance. Investors doubled down on the prospects for the med-tech company to outperform its large cap peers, pushing shares (NYSE:ABT) up by 5% in the wake of its June 17 earnings announcement.
Monitoring the electrical activity within and between cells on a large scale in a living animal may seem like a task that's next to impossible. But that's precisely what researchers at Cambridge, Mass.-based Harvard University aim to do with the next iteration of nanoscale sensors in the shape of wires.
Monitoring the electrical activity within and between cells on a large scale in a living animal may seem like a task that's next to impossible. But that's precisely what researchers at Cambridge, Mass.-based Harvard University aim to do with the next iteration of nanoscale sensors in the shape of wires.
The ultimate vision is pretty fantastical: A variety of synthetically engineered bacteria working together to diagnose – and even secrete proteins to treat – various inflammatory conditions or other immune-associated diseases. But researchers at the Wyss Institute at Harvard University and Harvard Medical School have taken another step along the path toward that goal.
